2026-04-29T04:10:14Zhttps://repisalud.isciii.es/rest/oai/request

oai:repisalud.isciii.es:20.500.12105/166372024-09-21T11:51:58Zcom_20.500.12105_19604com_20.500.12105_2051col_20.500.12105_19605

00925njm 22002777a 4500 dc Kumar, Rahul author Aktay-Cetin, Öznur author Craddock, Vaughn author Morales-Cano, Daniel author Kosanovic, Djuro author Cogolludo, Angel author Perez-Vizcaino, Francisco author Avdeev, Sergey author Kumar, Ashok author Ram, Anil Kumar author Agarwal, Stuti author Chakraborty, Ananya author Savai, Rajkumar author de Jesus Perez, Vinicio author Graham, Brian B author Butrous, Ghazwan author Dhillon, Navneet K author 2023-01 The Coronavirus Disease 2019 (COVID-19) caused by Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) and its sublineages pose a new challenge to healthcare systems worldwide due to its ability to efficiently spread in immunized populations and its resistance to currently available therapies. COVID-19, although targeting primarily the respiratory system, is also now well established that later affects every organ in the body. Most importantly, despite the available therapy and vaccine-elicited protection, the long-term consequences of viral infection in breakthrough and asymptomatic individuals are areas of concern. In the past two years, investigators accumulated evidence on how the virus triggers our immune system and the molecular signals involved in the cross-talk between immune cells and structural cells in the pulmonary vasculature to drive pathological lung complications such as endothelial dysfunction and thrombosis. In the review, we emphasize recent updates on the pathophysiological inflammatory and immune responses associated with SARS-CoV-2 infection and their potential long-term consequences that may consequently lead to the development of pulmonary vascular diseases. PLoS Pathog. 2023 Jan 12;19(1):e1011063. http://hdl.handle.net/20.500.12105/16637 36634048 10.1371/journal.ppat.1011063 1553-7374 PLoS pathogens Potential long-term effects of SARS-CoV-2 infection on the pulmonary vasculature: Multilayered cross-talks in the setting of coinfections and comorbidities.